Strongbridge Biopharma plc
SBBP · NASDAQ
6/30/2021 | 3/31/2021 | 12/31/2020 | 9/30/2020 | |
|---|---|---|---|---|
| Revenue | $10,042 | $8,382 | $8,226 | $8,071 |
| % Growth | 19.8% | 1.9% | 1.9% | – |
| Cost of Goods Sold | $467 | $411 | $442 | $408 |
| Gross Profit | $9,575 | $7,971 | $7,784 | $7,663 |
| % Margin | 95.3% | 95.1% | 94.6% | 94.9% |
| R&D Expenses | $5,397 | $5,839 | $5,320 | $6,771 |
| G&A Expenses | $15,988 | $10,946 | $11,605 | $9,221 |
| SG&A Expenses | $15,988 | $10,946 | $12,861 | $10,476 |
| Sales & Mktg Exp. | $0 | $0 | $1,256 | $1,255 |
| Other Operating Expenses | $1,255 | $1,256 | $0 | $0 |
| Operating Expenses | $22,640 | $18,041 | $18,181 | $17,247 |
| Operating Income | -$13,065 | -$10,070 | -$10,397 | -$9,584 |
| % Margin | -130.1% | -120.1% | -126.4% | -118.7% |
| Other Income/Exp. Net | -$175 | -$1,744 | -$1,564 | $6,425 |
| Pre-Tax Income | -$13,240 | -$11,814 | -$11,961 | -$3,159 |
| Tax Expense | $1 | $0 | -$15 | $0 |
| Net Income | -$13,241 | -$11,814 | -$11,946 | -$3,159 |
| % Margin | -131.9% | -140.9% | -145.2% | -39.1% |
| EPS | -0.2 | -0.18 | -0.21 | -0.056 |
| % Growth | -11.1% | 14.3% | -273% | – |
| EPS Diluted | -0.19 | -0.18 | -0.21 | -0.055 |
| Weighted Avg Shares Out | 67,654 | 67,375 | 56,105 | 56,105 |
| Weighted Avg Shares Out Dil | 67,921 | 67,375 | 56,105 | 57,405 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $810 | $782 | $560 | $523 |
| Depreciation & Amortization | $1,277 | $1,277 | $1,277 | $1,276 |
| EBITDA | -$11,153 | -$9,755 | -$10,124 | -$1,360 |
| % Margin | -111.1% | -116.4% | -123.1% | -16.9% |